SFCA3007: Additional Evidence of Improvements in Pre-Dose FEV1 with FP250

*P=0.012 vs SAL

Endpoint

(1%)

(11%)

(17%)

(9%)

? FEV1 (ml)

*

Previous slide

Next slide

Back to first slide

View graphic version